NEW YORK (360Dx) – Bruker said after the close of markets on Friday that the US Food and Drug Administration had cleared use of the company's MALDI Biotyper system for the detection of Candida auris.

According to Bruker, the MALDI Biotyper is now cleared by FDA for the clinical identification of 333 species or species groups covering 424 bacteria and yeast species.

A yeast, C. auris is a cause of infections in settings like hospitals and can be resistant to antifungal drugs typically used to treat Candida infections.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Feb
26
Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the Firestone Institute for Respiratory Health at McMaster University developed a cellular and molecular phenotyping pipeline using archived samples of lung tissue derived from patients diagnosed with fibrotic interstitial lung disease. 

Mar
19

In this webinar, Dr. Matthew Faron, a pathologist from the Medical College of Wisconsin, will share results of a comparison study of three rapid influenza assays.

 

Mar
20
Sponsored by
Qiagen

This webinar will discuss how a new multiplexed testing system can help physicians rapidly diagnose acute respiratory infections in the near-patient setting.

Mar
27
Sponsored by
Swift Biosciences

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost.